Details of the Drug Combination

General Information of Drug Combination (ID: DCEP3YJ)

Drug Combination Name

Indazole derivative 5 Topetecan

Indication

Disease Entry	Status	REF
Adult T acute lymphoblastic leukemia	Investigative	[1]

Component Drugs

Indazole derivative 5 DMM1I8R

Topetecan DMAE6LK

Small molecular drug

2D MOL

3D MOL

High-throughput Screening Result

Testing Cell Line: MOLT-4

Zero Interaction Potency (ZIP) Score: 5.97

Bliss Independence Score: 7.82

Loewe Additivity Score: 7.99

LHighest Single Agent (HSA) Score: 9.73

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)

Indazole derivative 5 Interacts with 2 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
ABL T315I mutant (ABL T315I)	TTZJTWA	ABL1_HUMAN	Inhibitor	[3]
Fusion protein Bcr-Abl T315I mutant (Bcr-Abl T315I)	TTIV39N	BCR_HUMAN-ABL1_HUMAN	Inhibitor	[3]
------------------------------------------------------------------------------------

Indication(s) of Topetecan

Disease Entry	ICD 11	Status	REF
Small-cell lung cancer	2C25.Y	Approved	[2]

Topetecan Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
DNA topoisomerase I (TOP1)	TTGTQHC	TOP1_HUMAN	Inhibitor	[4]
------------------------------------------------------------------------------------

References

1	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 020671.
3	Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
4	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).